TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 43 filers reported holding TERNS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89 | -41.1% | 17,640 | +2.6% | 0.00% | – |
| Q2 2023 | $151 | – | 17,200 | +14476.3% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 118 | -98.0% | 0.00% | – |
| Q1 2022 | $18,000 | -57.1% | 5,918 | 0.0% | 0.00% | – |
| Q4 2021 | $42,000 | -31.1% | 5,918 | +0.7% | 0.00% | – |
| Q3 2021 | $61,000 | -15.3% | 5,874 | +0.1% | 0.00% | – |
| Q2 2021 | $72,000 | -16.3% | 5,869 | +50.5% | 0.00% | – |
| Q1 2021 | $86,000 | – | 3,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 6,657,992 | $33,489,700 | 3.67% |
| ACUTA CAPITAL PARTNERS, LLC | 555,260 | $2,792,958 | 1.87% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 6,041,910 | $30,390,807 | 1.64% |
| VR Adviser, LLC | 3,092,273 | $15,554,133 | 1.64% |
| Fairmount Funds Management LLC | 2,040,000 | $10,261,200 | 1.24% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $3,592,854 | 1.20% |
| Deep Track Capital, LP | 6,000,000 | $30,180,000 | 1.16% |
| Orbimed Advisors | 7,619,135 | $38,324,249 | 0.81% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 500,000 | $2,515,000 | 0.76% |
| GREAT POINT PARTNERS LLC | 645,899 | $3,248,872 | 0.59% |